| 词条 | Ruboxistaurin |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477855864 | IUPAC_name = (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione | image = Ruboxistaurin.svg | image2 = Ruboxistaurin 3D ball.png | alt2 = Ball-and-stick model of the ruboxistaurin molecule | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 5263 | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 169939-94-0 | ATC_prefix = none | ATC_suffix = | PubChem = 153999 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 135727 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 721809WQCP | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 91829 | C=28 | H=28 | N=4 | O=3 | molecular_weight = 468.546 g/mol | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = ZCBUQCWBWNUWSU-SFHVURJKSA-N |drug_name=|alt=|caption=|type=|MedlinePlus=|licence_EU=|licence_US=|SMILES=CN(C[C@]1([H])CCN2C=C(C(C(O)=NC3=O)=C3C(C4=CC=CC=C45)=CN5CCO1)C6=CC=CC=C62)C}} Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family. On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2] {{update|date=February 2017}}Mechanism of actionRuboxistaurin is an inhibitor of protein kinase C-beta.[3] References1. ^{{cite web |url=https://www.drugs.com/nda/arxxant_060818.html |title=Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant |accessdate=2008-02-15 |work= }} 2. ^{{cite web |url=https://www.drugs.com/nda/arxxant_060929.html |title=Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy |accessdate=2008-02-15 |work= }} 3. ^{{cite journal |vauthors=Clarke M, Dodson PM |title=PKC inhibition and diabetic microvascular complications |journal=Best Pract Res Clin Endocrinol Metab |volume=21 |issue=4 |pages=573–86 |date=December 2007 |pmid=18054736 |doi=10.1016/j.beem.2007.09.007}} External links
2 : Eli Lilly and Company|Bisindolylmaleimides |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。